Patients' Perspectives on Discontinuing Buprenorphine for the Treatment of Opioid Use Disorder.
Journal
Journal of addiction medicine
ISSN: 1935-3227
Titre abrégé: J Addict Med
Pays: Netherlands
ID NLM: 101306759
Informations de publication
Date de publication:
18 Mar 2024
18 Mar 2024
Historique:
medline:
19
3
2024
pubmed:
19
3
2024
entrez:
18
3
2024
Statut:
aheadofprint
Résumé
Buprenorphine and other medications for opioid use disorder (OUD) are recommended as standard of care in the treatment of OUD and are associated with positive health and addiction-related outcomes. Despite benefits, discontinuation is common, with half of patients discontinuing in the first year of treatment. Addressing OUD is a major clinical priority, yet little is known about the causes of medication discontinuation from the patient perspective. From March 2021 to April 2022, we conducted qualitative interviews with patients who had discontinued buprenorphine for the treatment of OUD within the past 12 months. Eligible participants were selected from 2 Veterans Health Administration Health Care Systems in Oregon. Coding and analysis were guided by conventional qualitative content analysis. Twenty participants completed an interview; 90% were White and 90% were male, and the mean age was 54.2 years. Before discontinuation, participants had received buprenorphine for 8.3 months on average (range, 1-40 months); 80% had received buprenorphine for less than 12 months. Qualitative analysis identified the following themes relating to discontinuation: health system barriers (eg, logistical hurdles, rules and policy violations), medication effects (adverse effects; attributed adverse effects, lack of efficacy in treating chronic pain) and desire for opioid use. Patient description of decisions to discontinue buprenorphine could be multicausal, reflecting provider or system-level barriers in interaction with patient complexity or medication ambivalence. Study results identify several actionable ways OUD treatment could be modified to enhance patient retention.
Identifiants
pubmed: 38498620
doi: 10.1097/ADM.0000000000001292
pii: 01271255-990000000-00296
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Written work prepared by employees of the Federal Government as part of their official duties is, under the U.S. Copyright Act, a “work of the United States Government” for which copyright protection under Title 17 of the United States Code is not available. As such, copyright does not extend to the contributions of employees of the Federal Government.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Keyes KM, Rutherford C, Hamilton A, et al. What is the prevalence of and trend in opioid use disorder in the United States from 2010 to 2019? Using multiplier approaches to estimate prevalence for an unknown population size. Drug Alcohol Depend Rep. 2022;3:100052.
Krawczyk N, Rivera BD, Jent V, et al. Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019. Int J Drug Policy. 2022;110:103786.
Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. BMJ. 2017;357:1550.
National Academies of Sciences E and Medicine. Medications for Opioid Use Disorder Save Lives. Washington, DC: National Academies Press, 2019.
National Institute on Drug Abuse. Drug Overdose Death Rates. Trends and Statistics. Available at: https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates#:~:text=Opioid%2Dinvolved%20overdose%20deaths%20rose,with%2080%2C411%20reported%20overdose%20deaths. Published June 30, 2023. Accessed August 29, 2023.
CDC, National Center for Health Statistics. Provisional Data Shows U.S. Drug Overdose Deaths Top 100,000 in 2022. NCHS: A Blog of the National Center for Health Statistics. Available at: https://blogs.cdc.gov/nchs/2023/05/18/7365/#:~:text=The%2082%2C998%20predicted%20opioid%2Dinvolved,82%2C310%20in%20the%20previous%20year. Published May 18, 2023. Accessed September 7, 2023.
Wyse JJ, Gordon AJ, Dobscha SK, et al. Medications for opioid use disorder in the Department of Veterans Affairs (VA) health care system: Historical perspective, lessons learned, and next steps. Subst Abuse. 2018;39(2):139–144.
Gordon AJ, Drexler K, Hawkins EJ, et al. Stepped Care for Opioid use Disorder Train the trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities. Subst Abuse. 2020;41(3):275–282.
Gellad WF, Good CB, Shulkin DJ. Addressing the opioid epidemic in the United States: Lessons from the Department of Veterans Affairs. JAMA Intern Med. 2017;177(5):611–612.
Gordon AJ, Saxon AJ, Kertesz S, et al. Buprenorphine use and courses of care for opioid use disorder treatment within the Veterans Health Administration. Drug Alcohol Depend. 2023;248:109902.
Burns M, Tang L, Chang CCH, et al. Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: A retrospective cohort study. Addiction. 2022;117(12):3079–3088.
Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study. Ann Intern Med. 2018;169(3):137–145.
Wakeman SE, Larochelle MR, Ameli O, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622–e1920622.
Samples H, Williams AR, Crystal S, et al. Impact of long-term buprenorphine treatment on adverse health care outcomes in Medicaid: The impact of longer treatment on health care outcomes for opioid use disorder within a key population of Medicaid enrollees. Health Aff (Millwood). 2020;39(5):747–755.
Timko C, Schultz NR, Cucciare MA, et al. Retention in medication-assisted treatment for opiate dependence: A systematic review. J Addict Dis. 2016;35(1):22–35.
Lo-Ciganic WH, Gellad WF, Gordon AJ, et al. Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization. Addiction. 2016;111(5):892–902.
Substance Abuse Mental Health Services Administration (SAMHSA). Medications for Opioid Use Disorder: For Healthcare and Addiction Professionals, Policymakers, Patients and Families. Updated 2020. Available at: https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP20-02-01-006_508.pdf. Accessed May 25, 2022. Published online 2020.
Martin SA, Chiodo LM, Bosse JD, et al. The next stage of buprenorphine care for opioid use disorder. Ann Intern Med. 2018;169(9):628–635.
Hallowell BD, Chambers LC, Samuels EA, et al. Sociodemographic and prescribing characteristics that impact long-term retention in buprenorphine treatment for opioid use disorder among a statewide population. Drug Alcohol Depend. 2022;241:109680.
Biondi BE, Vander Wyk B, Schlossberg EF, et al. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community. Addict Sci Clin Pract. 2022;17(1):15.
Weinstein ZM, Kim HW, Cheng DM, et al. Long-term retention in office based opioid treatment with buprenorphine. J Subst Abuse Treat. 2017;74:65–70.
Frost MC, Zhang L, Kim HM, et al. Use of and retention on video, telephone, and in-person buprenorphine treatment for opioid use disorder during the COVID-19 pandemic. JAMA Netw Open. 2022;5(10):e2236298–e2236298.
Vakkalanka JP, Lund BC, Ward MM, et al. Telehealth utilization is associated with lower risk of discontinuation of buprenorphine: A retrospective cohort study of US veterans. J Gen Intern Med. 2022;37(7):1610–1618.
Young GJ, Hasan MM, Young LD, et al. Treatment experiences for patients receiving buprenorphine/naloxone for opioid use disorder: A qualitative study of patients' perceptions and attitudes. Subst Use Misuse. 2023;58(4):512–519.
Clay S, Treloar C, Degenhardt L, et al. ‘I just thought that was the best thing for me to do at this point’: Exploring patient experiences with depot buprenorphine and their motivations to discontinue. Int J Drug Policy. 2023;115:104002.
Teruya C, Schwartz RP, Mitchell SG, et al. Patient perspectives on buprenorphine/naloxone: A qualitative study of retention during the starting treatment with agonist replacement therapies (START) study. J Psychoactive Drugs. 2014;46(5):412–426.
Gryczynski J, Mitchell SG, Jaffe JH, et al. Leaving buprenorphine treatment: Patients' reasons for cessation of care. J Subst Abuse Treat. 2014;46(3):356–361.
Wyse JJ, Lovejoy TI, Gordon AJ, et al. “I'm clean and sober, but not necessarily free”: Perceptions of buprenorphine among patients in long-term treatment. Subst Abuse. 2023;44(1):41–50.
Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277–1288.
Tong A, Sainsbury P, Craig J. Consolidated Criteria for Reporting Qualitative Research (COREQ): A 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349–357.
Department of Veterans Affairs, Department of Defense. VA/DOD Clinical Practice Guideline: Management of Substance Use Disorder (SUD) 2021. Available at: https://www.healthquality.va.gov/guidelines/MH/sud/. Accessed May 24, 2022.
Jakubowski A, Fox A. Defining low-threshold buprenorphine treatment. J Addict Med. 2020;14(2):95–98.
Hagedorn HJ, Gustavson AM, Ackland PE, et al. Advancing pharmacological treatments for opioid use disorder (ADaPT-OUD): An implementation trial in eight Veterans Health Administration facilities. J Gen Intern Med. 2022 Nov;37(14):3594–3602.
Wyse JJ, Shull S, Lindner S, et al. Access to medications for opioid use disorder in rural versus urban Veterans Health Administration facilities. J Gen Intern Med. 2023 Jun;38(8):1871–1876.
Kelley AT, Incze MA, Baylis JD, et al. Patient-centered quality measurement for opioid use disorder: Development of a taxonomy to address gaps in research and practice. Subst Abuse. 2022;43(1):1286–1299.
Samples H, Williams AR, Olfson M, et al. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees. J Subst Abuse Treat. 2018;95:9–17.
Kennedy AJ, Wessel CB, Levine R, et al. Factors associated with long-term retention in buprenorphine-based addiction treatment programs: A systematic review. J Gen Intern Med. 2022;37:332–340.
Weimer MB, Herring AA, Kawasaki SS, et al. ASAM clinical considerations: Buprenorphine treatment of opioid use disorder for individuals using high-potency synthetic opioids. J Addict Med. 2023;17(6):632–639. Available at: https://journals.lww.com/journaladdictionmedicine/fulltext/2023/11000/asam_clinical_considerations__buprenorphine.2.aspx.
Oviedo-Joekes E, Palis H, Guh D, et al. Treatment with injectable hydromorphone: Comparing retention in double blind and open label treatment periods. J Subst Abuse Treat. 2019;101:50–54.
Manhapra A, Quinones L, Rosenheck R. Characteristics of veterans receiving buprenorphine vs. methadone for opioid use disorder nationally in the Veterans Health Administration. Drug Alcohol Depend. 2016;160:82–89.